Outlook Therapeutics · ONS-5010 · 2023 – Aug 2025
Was the FDA's August 2025 letter its first Complete Response Letter on ONS-5010?
No. Outlook's filings describe an earlier Complete Response Letter in August 2023, which cited manufacturing issues, inspection observations and a lack of substantial evidence. The 2025 letters are the second and third.
EphemerisX Research · Published · 3 source documents · 1 min read
Short answer
No. Outlook's 10-K calls the August 2025 letter its “second CRL”, and a March 2026 filing calls the December 2025 letter the “third”. The first, in August 2023, is not in this record; the company describes it as citing CMC issues, inspection observations and a lack of substantial evidence, after which NORSE EIGHT was run under an agreed protocol.
What the evidence shows
The 10-K: On August 29, 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence
10-K · Dec 19, 2025. After that letter, it says, we learned that the FDA required the completion of an additional adequate and well-controlled clinical trial
10-K · Dec 19, 2025.
That trial was NORSE EIGHT. The company says it submitted a Special Protocol Assessment, or SPA, to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it would address the FDA’s requirement for a second adequate and well-controlled clinical trial
10-K · Dec 19, 2025, and that In January 2024, we received confirmation that the FDA had reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA
10-K · Dec 19, 2025. Elsewhere the 10-K adds that the agreement only indicated concurrence with critical trial design concepts
10-K · Dec 19, 2025.
By the same 10-K's account, of the 2023 letter's three grounds only the evidence question remained in 2025: On August 27, 2025, we received a second CRL from the FDA. This CRL included only one deficiency, for a lack of substantial evidence of effectiveness
10-K · Dec 19, 2025. In November 2024 the company had said Remediation of the Chemistry, Manufacturing and Controls (CMC) comments in the Complete Response Letter (CRL) is complete
8-K · Nov 27, 2024.
In March 2026 the count reached three: we reported that we had received a third Complete Response Letter
8-K · Mar 16, 2026. What the second letter objected to: What did the FDA's August 2025 letter object to?
Not in this record: the August 2023 letter itself.
Follow the thread
- What did the FDA's August 2025 letter object to?“Second CRL”: only one deficiency
- Did the FDA ask Outlook for another clinical trial, or for confirmatory evidence?2023: an additional well-controlled trial required
- How did Outlook's description of NORSE EIGHT change?NORSE EIGHT's agreed protocol
This investigation connects to
- What happens after a second FDA Complete Response Letter?Cross-investigation · Divergent outcome · with Aldeyra Therapeutics, CorMedix, Replimune, Verrica Pharmaceuticals
- How did two programs move forward after repeat FDA letters without running a new trial?Cross-investigation · Comparable evidence · with Replimune
- When is one trial enough? How the FDA weighed the evidence in three programsCross-investigation · Comparable evidence · with Aldeyra Therapeutics, Replimune
The documents, by date
The passages quoted
Outlook Therapeutics Form 8-K, filed November 27, 2024
Remediation of the Chemistry, Manufacturing and Controls (CMC) comments in the Complete Response Letter (CRL) is complete and has been closely aligned with the FDA in type C and type D meetingsOpen at the source →
Outlook Therapeutics Form 10-K, filed December 19, 2025
On August 29, 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.Open at the source →
Outlook Therapeutics Form 10-K, filed December 19, 2025
On August 27, 2025, we received a second CRL from the FDA. This CRL included only one deficiency, for a lack of substantial evidence of effectiveness. In the CRL, the FDA advised that, because ONS-5010 did not meet the primary efficacy endpoint in NORSE EIGHT, it is recommended that confirmatory evidence of efficacy be submitted to support the application for ONS-5010. Additionally, the FDA reiterated that NORSE TWO met its primary endpoint for effectiveness.Open at the source →
Outlook Therapeutics Form 10-K, filed December 19, 2025
In December 2023, we submitted a Special Protocol Assessment, or SPA, to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it would address the FDA’s requirement for a second adequate and well-controlled clinical trial to support our planned resubmission of the ONS-5010/LYTENAVA BLA. In January 2024, we received confirmation that the FDA had reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA.Open at the source →
Outlook Therapeutics Form 10-K, filed December 19, 2025
Although in January 2024 we reached agreement on a SPA with FDA, this agreement only indicated concurrence with critical trial design concepts; it did not imply that FDA had reviewed, or concurred with, protocol details that do not affect approvability. Moreover, the presence of a SPA agreement does not guarantee that a marketing application will be filed or approved, even if the trial is conducted in accordance with the protocol.Open at the source →
Outlook Therapeutics Form 10-K, filed December 19, 2025
At subsequent Type A meetings with the FDA, we learned that the FDA required the completion of an additional adequate and well-controlled clinical trial evaluating ONS-5010/LYTENAVA, as well as additional requested CMC data indicated in the CRL to approve ONS-5010/LYTENAVA for use in wet AMD.Open at the source →
Outlook Therapeutics Form 8-K, filed March 16, 2026
Moreover, on December 31, 2025, we reported that we had received a third Complete Response Letter, or CRL, with respect to our Biologics License Application, or BLA, for ONS-5010, and the U.S. Food and Drug Administration, or FDA, has again recommended that confirmatory evidence of efficacy be submitted to support the application. However, the FDA did not indicate in the CRL what type of confirmatory evidence would be acceptable, and it is possible that we may need to conduct additional clinical and/or non-clinical studies of ONS-5010 in order to satisfy the FDA’s requirementsOpen at the source →